SOLICITATION NOTICE
A -- Purity Specifications, Storage and Distribution for Medications Development
- Notice Date
- 9/29/2006
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6101 Executive Boulevard Room 260 - MSC 8402, Bethesda, MD, 20892
- ZIP Code
- 20892
- Solicitation Number
- N01DA-7-8873
- Response Due
- 12/7/2006
- Point of Contact
- Amy Pasciak, Contract Specialist, NIDA/NIH, Phone 301.443.6677, Fax 301.443.7595, - Kenneth Goodling, Contracting Officer, Phone (301)443-6677, Fax (301)443-7595,
- E-Mail Address
-
ap370t@nih.gov, kg25d@nih.gov
- Description
- The National Institute on Drug Abuse is soliciting proposals from qualified individuals or organizations having the capability to act as a centralized repository for compounds from domestic and international investigators, commercial sources, and pharmaceutical companies. The contract shall involve the receipt, purchase, storage and analysis of compounds from various sources, and the shipment of these compounds to domestic and international test sites, as well as maintenance of an extensive inventory and tracking system. The major goal of this project is to provide NIDA with a holding site which has the capability to inventory, analyze and store compounds, prepared under both non-GMP and GMP conditions, in amounts ranging from milligram quantities to several kilograms. Because some compounds may be scheduled under the Controlled Substances Act, proper DEA registration and adequate security is required. All studies must be carried out under pertinent FDA regulations, such as current Good Clinical Practice (cGCP) and current Good Laboratory Practice (cGLP) regulations. To handle substances under the Controlled Substances Act of 1970, DEA Research Registration for Schedules II to V will be required. NIDA may also require a DEA registration for Schedule I controlled substances. The pertinent FDA's guidelines/guidance shall be followed. It is estimated that a five year incrementally funded completion type contract with additional option quantities will be awarded. RFP No. N01DA-7-8873 will be available electronically on or about October 23, 2006. You can access the RFP through the FedBizOpps http://www.fedbizopps.gov or through the NIDA website at the following address: http://www.nida.nih.gov/RFP/RFPList.html. The electronic RFP contains all information needed to submit a proposal. No printed version of the solicitation document or source list is available. NIDA will consider proposals submitted by any responsible offeror. Proposals will be due on or about December 7, 2006. This advertisement does not commit the Government to award a contract. See note 26. NOTE: THIS NOTICE MAY HAVE POSTED ON FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (29-SEP-2006). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 22-FEB-2007, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link to FedBizOpps document.
(http://www.fbo.gov/spg/HHS/NIH/NIDA-01/N01DA-7-8873/listing.html)
- Record
- SN01237351-F 20070224/070222223225 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |